Clinical Trials

The Tumor Immunotherapy Program has a number of studies that are currently recruiting patients. For information about how to be referred to one of these studies, please contact us.



Show studies for patients with

Currently Recruiting

  • TILs-001-DC

    A Phase I Study Evaluating the Feasibility and Safety of Infusion of Re-StimulatedAutologous Tumor-Infiltrating Lymphocytes (TILs) Followed by Low-Dose Interleukin-2 Therapy in Patients with Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Learn more(opens information in a pop-up overlay)
  • TILs-002-MEL

    Phase II Study Evaluating the Infusion Of Autologous Tumor-Infiltrating Lymphocytes (TILs) And Low-Dose Interleukin-2 (IL-2) Therapy Following A Preparative Regimen Of Non-Myeloablative Lymphodepletion Using Cyclophosphamide And Fludarabine In Patients With Metastatic Melanoma

    Learn more(opens information in a pop-up overlay)
  • TILs-003-Meso

    Phase I/II study evaluating the infusion of tumor-infiltrating lymphocytes (TILs) and low-dose interleukin-2 (IL-2) therapy following a preparative regimen of non-myeloablative lymphodepletion using cyclophosphamide and fludarabine in patients with malignant pleural mesothelioma

    Learn more(opens information in a pop-up overlay)
  • METADUR

    An open-label, phase II basket study of a hypomethylating agent azacitidine and durvalumab (anti-PDL1) in advanced solid tumors.

    Learn more(opens information in a pop-up overlay)
  • INSPIRE

    INvestigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation

    Learn more(opens information in a pop-up overlay)
  • 1301-02

    Phase 1b Study of NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes in Patients with Solid Tumors

    Learn more(opens information in a pop-up overlay)

Recruiting Soon

  • ACTIVATE

    Phase Ib trial of pembrolizumab administered in combination or following adoptive cell therapy: A multiple cohort study

    Learn more(opens information in a pop-up overlay)
  • MG1MA3 with AdMA3

    A phase Ib study of MG1 MARABA/MAGE-A3 (MG1MA3) with adenovirus vaccine/MAGE A3 (AdMA3) in combination with the immune checkpoint inhibitor Pembrolizumab in patients with incurable advanced or metastatic MAGE-A3 expressing solid tumors

    Learn more(opens information in a pop-up overlay)
  • Phase I Study of Autologous Acute Myelogenous Leukemia (AML) Cells Containing Lentivirus Engineering

    This is a phase 1 study (the first stage in testing a new treatment to see how safe and tolerable the treatment is) which will include patients with acute myeloid leukemia (AML) that has either returned or has a more than a 70% chance of coming back and cannot have a bone marrow transplant.

    This study will see whether modifying a patient's AML cells to produce IL-12 and giving it back to the patient is safe and useful in patients with AML that cannot have bone marrow transplants.

    Learn more(opens information in a pop-up overlay)

Closed Recruiting